Tivozanib  

作　　者：杨骐鸣 石玉[2] 徐春秀[3] 刘日[3] 邹美香[2] 卢汝梅[1] 李祎亮[2] 

机构地区：[1]广西中医学院,广西南宁530001 [2]天津药物研究院天津市新药设计与发现重点实验室,天津300193 [3]天津中医药大学,天津300193

出　　处：《现代药物与临床》2012年第2期129-132,共4页Drugs & Clinic

摘　　要：肿瘤的增长与扩散依赖于新血管的生成或血管的新生。血管内皮生长因子受体(VEGFR)能促进内皮细胞的增殖,增强血管的渗透性,是控制新生血管生成的重要调控因子之一。Tivozanib是一种新型高选择抑制VEGFR的喹唑啉脲类化合物,体内外实验表明本品具有显著的抗血管生成和抑制抗肿瘤生长的活性,目前对肾细胞癌的治疗正在进行Ⅲ期临床实验。The sustained growth and dissemination of tumors are dependent on the process of new vessel formation or angiogenesis.Vascular endothelial growth factor receptors（VEGFR） which is one of important regulatory factors could promote the proliferation and survival of endothelial cells,increase the vascular permeability,and control the generation of new blood vessels.Tivozanib is a novel oral quinoline urea derivative that is a highly potent and selective VEGFR.The compound has demonstrated antiangiogenic and antitumor activities in vitro and in vivo and is an ongoing phase Ⅲ registration trial in renal cell carcinoma.

关 键 词：Tivozanib 血管内皮生长因子受体 抗肿瘤 

分 类 号：R91[医药卫生—药学]